• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

美国疑似黄热病疫苗相关内脏嗜性不良事件(1973 年和 1978 年)。

Suspected yellow fever vaccine-associated viscerotropic adverse events (1973 and 1978), United States.

机构信息

Kleiner Perkins Caufield and Byers, 2750 Sand Hill Road, Menlo Park, CA 94025, USA.

出版信息

Am J Trop Med Hyg. 2010 May;82(5):919-21. doi: 10.4269/ajtmh.2010.10-0001.

DOI:10.4269/ajtmh.2010.10-0001
PMID:20439976
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC2861370/
Abstract

Two cases of yellow fever vaccine-associated viscerotropic adverse events (YEL-AVD) were identified by review of correspondence received at the Centers for Disease Control and Prevention (CDC; Ft. Collins, CO). The cases occurred in Indiana and Maryland in 1973 and 1978, respectively. One patient, a 75-year-old man with multi-organ failure died, and the other, a 31-year-old woman, was hospitalized for 14 days. Onset was 3-6 days after vaccination. The illness was characterized by fever, headache, myalgia, gastrointestinal symptoms, hepatic and renal dysfunction, and (in the fatal case), shock and coagulopathy, compatible with YEL-AVD. Liver pathology showed diffuse, spotty necrosis, acidophilic degeneration, Kupffer cell hyperplasia, and microvesicular fat. No virological confirmation was obtained, so that both cases remain classified as "suspect." The 1973 case is the earliest record of YEL-AVD; until now, the earliest known case of YEL-AVD had been in 1975 in Brazil, and most subsequent cases have been reported after 1995.

摘要

通过审查疾病预防控制中心(CDC;科罗拉多州柯林斯堡)收到的信件,发现了两例与黄热病疫苗相关的内脏不良事件(YEL-AVD)。这两例病例分别发生于 1973 年和 1978 年的印第安纳州和马里兰州。一名 75 岁的多器官衰竭男性患者死亡,另一名 31 岁的女性患者住院治疗了 14 天。发病时间为接种疫苗后 3-6 天。该疾病的特征是发热、头痛、肌痛、胃肠道症状、肝肾功能障碍,以及(在致命病例中)休克和凝血功能障碍,符合 YEL-AVD。肝脏病理学表现为弥漫性、斑点状坏死、嗜酸性变性、枯否细胞增生和微泡脂肪变性。未获得病毒学确认,因此两例病例均被归类为“疑似”。1973 年的病例是 YEL-AVD 的最早记录;到目前为止,已知最早的 YEL-AVD 病例发生于 1975 年的巴西,此后大多数病例发生在 1995 年之后。

相似文献

1
Suspected yellow fever vaccine-associated viscerotropic adverse events (1973 and 1978), United States.美国疑似黄热病疫苗相关内脏嗜性不良事件(1973 年和 1978 年)。
Am J Trop Med Hyg. 2010 May;82(5):919-21. doi: 10.4269/ajtmh.2010.10-0001.
2
Rare case of fatal yellow fever vaccine-associated viscerotropic disease.罕见的致命性黄热病疫苗相关内脏型疾病病例。
South Med J. 2005 Jun;98(6):653-6. doi: 10.1097/01.SMJ.0000157537.11806.DC.
3
Yellow fever-associated viscerotropic disease in Barcelona, Spain.西班牙巴塞罗那的黄热病相关内脏型疾病
J Travel Med. 2008 May-Jun;15(3):202-5. doi: 10.1111/j.1708-8305.2008.00209.x.
4
Adverse events associated with 17D-derived yellow fever vaccination--United States, 2001-2002.2001 - 2002年美国与17D株黄热病疫苗相关的不良事件
MMWR Morb Mortal Wkly Rep. 2002 Nov 8;51(44):989-93.
5
Fatal multiorgan failure due to yellow fever vaccine-associated viscerotropic disease.黄热病疫苗相关内脏型疾病导致的致命性多器官衰竭。
Vaccine. 2007 Dec 5;25(50):8480-5. doi: 10.1016/j.vaccine.2007.08.061. Epub 2007 Sep 18.
6
Yellow fever vaccine-associated viscerotropic disease (YEL-AVD) and corticosteroid therapy: eleven United States cases, 1996-2004.黄热病疫苗相关内脏型疾病(YEL-AVD)与皮质类固醇治疗:1996 - 2004年美国的11例病例
Am J Trop Med Hyg. 2006 Aug;75(2):333-6.
7
A case suspected for yellow fever vaccine-associated viscerotropic disease in the Netherlands.荷兰一起疑似黄热病疫苗相关内脏疾病病例。
J Travel Med. 2014 Nov-Dec;21(6):421-4. doi: 10.1111/jtm.12135. Epub 2014 Jun 11.
8
Yellow fever vaccine-associated neurologic and viscerotropic disease: a 10-year case series of the French National Reference Center for Arboviruses with clinical and immunological insights.黄热病疫苗相关的神经和内脏疾病:法国国家虫媒病毒参考中心 10 年的病例系列,具有临床和免疫学见解。
J Travel Med. 2024 Mar 1;31(2). doi: 10.1093/jtm/taad160.
9
Risk of yellow fever vaccine-associated viscerotropic disease among the elderly: a systematic review.老年人中黄热病疫苗相关内脏疾病的风险:系统评价。
Vaccine. 2013 Dec 2;31(49):5798-805. doi: 10.1016/j.vaccine.2013.09.030. Epub 2013 Sep 27.
10
First case of yellow fever vaccine-associated viscerotropic disease (YEL-AVD) in Hong Kong.香港出现首例黄热病疫苗相关内脏疾病(YEL-AVD)病例。
J Travel Med. 2016 Apr 17;23(4). doi: 10.1093/jtm/taw020. Print 2016 Apr.

引用本文的文献

1
Recent Advancements in Mosquito-Borne Flavivirus Vaccine Development.蚊虫传播的黄病毒疫苗研发的最新进展
Viruses. 2023 Mar 23;15(4):813. doi: 10.3390/v15040813.
2
Viscerotropic disease and acute uveitis following yellow fever vaccination: a case report.黄热病疫苗接种后内脏嗜性疾病和急性葡萄膜炎:病例报告。
BMC Infect Dis. 2020 Feb 10;20(1):116. doi: 10.1186/s12879-020-4838-x.
3
Immunogenicity and Protection After Vaccination With a Modified Vaccinia Virus Ankara-Vectored Yellow Fever Vaccine in the Hamster Model.用改良安卡拉痘苗病毒载体黄热病疫苗免疫仓鼠后诱导的免疫原性和保护作用
Front Immunol. 2018 Aug 2;9:1756. doi: 10.3389/fimmu.2018.01756. eCollection 2018.
4
Yellow fever vaccine-associated viscerotropic disease: current perspectives.黄热病疫苗相关内脏嗜性疾病:当前观点
Drug Des Devel Ther. 2016 Oct 12;10:3345-3353. doi: 10.2147/DDDT.S99600. eCollection 2016.
5
Questions regarding the safety and duration of immunity following live yellow fever vaccination.关于黄热病活疫苗接种后的安全性和免疫持续时间的问题。
Expert Rev Vaccines. 2016 Dec;15(12):1519-1533. doi: 10.1080/14760584.2016.1198259. Epub 2016 Jun 20.
6
A humanized monoclonal antibody neutralizes yellow fever virus strain 17D-204 in vitro but does not protect a mouse model from disease.一种人源化单克隆抗体在体外可中和黄热病毒17D - 204株,但不能保护小鼠模型免受疾病侵害。
Antiviral Res. 2016 Jul;131:92-9. doi: 10.1016/j.antiviral.2016.04.013. Epub 2016 Apr 26.
7
Active assessment of adverse events following yellow fever vaccination of persons aged 60 years and more.对 60 岁及以上人群接种黄热病疫苗后的不良事件进行主动评估。
Hum Vaccin Immunother. 2013 Feb;9(2):277-82. doi: 10.4161/hv.22714. Epub 2013 Jan 4.
8
Immune correlates of protection against yellow fever determined by passive immunization and challenge in the hamster model.免疫保护相关的黄热病通过在仓鼠模型中的被动免疫和攻毒实验确定。
Vaccine. 2011 Aug 11;29(35):6008-16. doi: 10.1016/j.vaccine.2011.06.034. Epub 2011 Jun 28.

本文引用的文献

1
THE USE OF YELLOW FEVER VIRUS MODIFIED BY IN VITRO CULTIVATION FOR HUMAN IMMUNIZATION.经体外培养改良的黄热病病毒用于人体免疫。
J Exp Med. 1937 May 31;65(6):787-800. doi: 10.1084/jem.65.6.787.
2
Viscerotropic disease following yellow fever vaccination in Peru.秘鲁黄热病疫苗接种后的嗜内脏性疾病。
Vaccine. 2009 Oct 9;27(43):5974-81. doi: 10.1016/j.vaccine.2009.07.082. Epub 2009 Aug 11.
3
Adverse event reports following yellow fever vaccination.黄热病疫苗接种后的不良事件报告。
Vaccine. 2008 Nov 11;26(48):6077-82. doi: 10.1016/j.vaccine.2008.09.009. Epub 2008 Sep 20.
4
Case of yellow fever vaccine--associated viscerotropic disease with prolonged viremia, robust adaptive immune responses, and polymorphisms in CCR5 and RANTES genes.黄热病疫苗相关内脏型疾病病例,伴有病毒血症持续时间延长、强大的适应性免疫反应以及CCR5和RANTES基因多态性
J Infect Dis. 2008 Aug 15;198(4):500-7. doi: 10.1086/590187.
5
Acute viscerotropic disease following vaccination against yellow fever.黄热病疫苗接种后的急性嗜内脏性疾病
Trans R Soc Trop Med Hyg. 2007 Oct;101(10):967-71. doi: 10.1016/j.trstmh.2007.06.013. Epub 2007 Jul 31.
6
Characterization of a viscerotropic yellow fever vaccine variant from a patient in Brazil.巴西一名患者体内亲内脏性黄热病疫苗变异株的特征分析。
Vaccine. 2006 Apr 5;24(15):2803-9. doi: 10.1016/j.vaccine.2006.01.009. Epub 2006 Jan 18.
7
History of thymoma and yellow fever vaccination.胸腺瘤病史及黄热病疫苗接种史。
Lancet. 2004;364(9438):936. doi: 10.1016/S0140-6736(04)17017-7.
8
Comparative safety and immunogenicity of two yellow fever 17D vaccines (ARILVAX and YF-VAX) in a phase III multicenter, double-blind clinical trial.两种黄热病17D疫苗(ARILVAX和YF-VAX)在一项III期多中心双盲临床试验中的安全性和免疫原性比较
Am J Trop Med Hyg. 2002 May;66(5):533-41. doi: 10.4269/ajtmh.2002.66.533.
9
Hepatitis and death following vaccination with 17D-204 yellow fever vaccine.
Lancet. 2001 Jul 14;358(9276):121-2. doi: 10.1016/S0140-6736(01)05341-7.
10
Fever and multisystem organ failure associated with 17D-204 yellow fever vaccination: a report of four cases.与17D - 204黄热病疫苗接种相关的发热和多系统器官衰竭:4例报告
Lancet. 2001 Jul 14;358(9276):98-104. doi: 10.1016/s0140-6736(01)05327-2.